Edwards Lifesciences Reports Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Edwards Lifesciences (EW) PT Raised to $260 at RBC Capital
October 24, 2019 6:25 AM EDTRBC Capital analyst Brandon Henry raised the price target on Edwards Lifesciences (NYSE: EW) to $260.00 (from $250.00) while maintaining an Outperform rating.
US TAVR growth of +30%"We now model 2019 and 2020 revenues of $4.32B (previously $4.22B) and $4.74B (previously $4.64B), respectively. Moving to the... MoreEdwards Lifesciences (EW) Tops Q3 EPS by 19c, Updates FY Guidance
October 23, 2019 4:20 PM EDTEdwards Lifesciences (NYSE: EW) reported Q3 EPS of $1.41, $0.19 better than the analyst estimate of $1.22. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.04 billion.
GUIDANCE:
Edwards Lifesciences sees FY2019 EPS of $5.50-$5.65, versus the consensus of $5.34.... More
